Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction?

Bakker J. A., Bierau J., Drent M.

Source: Eur Respir J 2007; 30: 821-822
Journal Issue: November

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Bakker J. A., Bierau J., Drent M.. Therapeutic regimens in interstitial lung disease guided by genetic screening: fact or fiction?. Eur Respir J 2007; 30: 821-822

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
What’s new in interstitial lung diseases in children?
Source: Virtual Congress 2021 – Paediatric year in review
Year: 2021

Diagnosis of interstitial lung diseases and impact of guidelines: an issue only for pulmonologists?
Source: Annual Congress 2007 - Controversies in the management of interstitial lung diseases
Year: 2007

Interstitial lung diseases and COVID-19: myths and reality
Source: Virtual Congress 2021 – Chinese programme 2021
Year: 2021

Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
Source: Eur Respir J 2014; 44: 1011-1022
Year: 2014

Treatment of early lung disease – is it possible? Does it work?
Source: Annual Congress 2004 - PG19 - Screening for cystic fibrosis: diagnose early - treat early
Year: 2004

The future of treatment for interstitial lung diseases: the patient’s and physician’s perspective
Source: International Congress 2019 – Rare lung diseases
Year: 2019

New antifibrotic drugs: will interstitial diseases patients still need lung transplantation?
Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs
Year: 2020

Targeted therapies for lung cancer: how did the game begin?
Source: Breathe 2016; 12: 177-179
Year: 2016

Advances in treatment of complex lung disease: will targeted therapy with anticalins be clinically applied in the near future?
Source: International Congress 2019 – Inhaled medicines and biological therapies in the current era of systemic treatments
Year: 2019

Lung disease induced by newer therapies for lung cancer: an update
Source: Annual Congress 2006 - Drug-induced lung injury – new aspects
Year: 2006

Severe fibrotic lung disease – How much therapy is too much therapy?
Source: Annual Congress 2008 - Clinical Grand Round - an interactive session
Year: 2008

Interstitial lung disease: new challenges and evolving phenotypes
Source: Eur Respir Rev 2009; 19: 91-93
Year: 2010

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
Source: Eur Respir Rev, 27 (150) 180074; 10.1183/16000617.0074-2018
Year: 2018

Multidisciplinary board for interstitial lung disease: Relevance for real life?
Source: International Congress 2015 – New insights into IIPs
Year: 2015

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021

Novel aspects in lung cancer pathology: how does it help for selecting chemotherapy?
Source: Annual Congress 2010 - PG4 Core Curriculum Postgraduate Course: Pathology for the clinician
Year: 2010

Diffuse parenchymal lung disease: a practical overview Is a lung biopsy necessary for management?
Source: Breathe 2008; 4: 233-239
Year: 2008

Radiological diagnosis of interstitial lung disease: is it all about pattern recognition?
Source: Eur Respir J, 52 (2) 1801321; 10.1183/13993003.01321-2018
Year: 2018